Serum Nutritional Markers as Prognostic Factors for Hepatic and Extrahepatic Carcinogenesis in Japanese Patients with Nonalcoholic Fatty Liver Disease

References

• Adams LA, Anstee QM, Tilg H, and Targher G: Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 66, 1138–1153, 2017. doi:10.1136/gutjnl-2017-313884
   PubMed Web of Science ®Google Scholar
• Tilg H, and Moschen AR: Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52, 1836–1846, 2010. doi:10.1002/hep.24001
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, and Mishra A: Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 62, 1723–1730, 2015. doi:10.1002/hep.28123
   PubMed Web of Science ®Google Scholar
• Li J, Zou B, Yeo YH, Feng Y, Xie X, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 4, 389–398, 2019. doi:10.1016/S2468-1253(19)30039-1
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67, 328–357, 2018. doi:10.1002/hep.29367
   PubMed Web of Science ®Google Scholar
• Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129, 113–121, 2005.
   PubMed Web of Science ®Google Scholar
• Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61, 1547–1554, 2015. doi:10.1002/hep.27368
   PubMed Web of Science ®Google Scholar
• Mantovani A, Ballestri S, Lonardo A, and Targher G: Cardiovascular disease and myocardial abnormalities in nonalcoholic fatty liver disease. Dig Dis Sci 61, 1246–1267, 2016. doi:10.1007/s10620-016-4040-6
   PubMed Web of Science ®Google Scholar
• Wong VW, Wong GL, Yip GW, Lo AO, Limquiaco J, et al. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 60, 1721–1727, 2011. doi:10.1136/gut.2011.242016
   PubMed Web of Science ®Google Scholar
• Kim GA, Lee HC, Choe J, Kim MJ, Lee MJ, et al. Association between non-alcoholic fatty liver disease and cancer incidence rate. J Hepatol 68, 140–146, 2017. doi:10.1016/j.jhep.2017.09.012
   Web of Science ®Google Scholar
• Alberino F, Gatta A, Amodio P, Merkel C, Di Pascoli L, et al. Nutrition and survival in patients with liver cirrhosis. Nutrition 17, 445–450, 2001.
   PubMed Web of Science ®Google Scholar
• Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, et al. Impact of the branched-chain amino acid to tyrosine ratio and branched-chain amino acid granule therapy in patients with hepatocellular carcinoma: a propensity score analysis. J Gastroenterol Hepatol 30, 1412–1419, 2015. doi:10.1111/jgh.12954
   PubMed Web of Science ®Google Scholar
• Hanai T, Shiraki M, Nishimura K, Ohnishi S, Imai K, et al. Sarcopenia impairs prognosis of patients with liver cirrhosis. Nutrition 31, 193–199, 2015. doi:10.1016/j.nut.2014.07.005
   PubMed Web of Science ®Google Scholar
• Azuma Y, Maekawa M, Kuwabara Y, Nakajima T, Taniguchi K, et al. Determination of branched-chain amino acids and tyrosine in serum of patients with various hepatic diseases, and its clinical usefulness. Clin Chem 35, 1399–1403, 1989.
   PubMed Web of Science ®Google Scholar
• Ishikawa T: Branched-chain amino acids to tyrosine ratio value as a potential prognostic factor for hepatocellular carcinoma. World J Gastroenterol 18, 2005–2008, 2012. doi:10.3748/wjg.v18.i17.2005
   PubMed Web of Science ®Google Scholar
• Himoto T, and Masaki T: Associations between zinc deficiency and metabolic abnormalities in patients with chronic liver disease. Nutrients 10, 88, 2018. doi:10.3390/nu100100
   PubMed Web of Science ®Google Scholar
• Goode HF, Kelleher J, and Walker BE: Relation between zinc status and hepatic functional reserve in patients with liver disease. Gut 31, 694–697, 1990.
   PubMed Web of Science ®Google Scholar
• Marchesini G, Fabbri A, Bianchi G, Brizi M, and Zoli M: Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. Hepatology 23, 1084–1092, 1996. doi:10.1053/jhep.1996.v23.pm0008621138
   PubMed Web of Science ®Google Scholar
• Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149, 389–397, 2015. doi:10.1053/j.gastro.2015.04.043
   PubMed Web of Science ®Google Scholar
• Ito T, Ishigami M, Ishizu Y, Kuzuya T, Honda T, et al. Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patients. J Gastroenterol Hepatol 34, 207–214, 2019. doi:10.1111/jgh.14448
   PubMed Web of Science ®Google Scholar
• Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43, 1317–1325, 2006. doi:10.1002/hep.21178
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn R, Sirlin CB, Abecassis M, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67, 358–380, 2018. doi:10.1002/hep.29086
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 53, 1874–1882, 2011. doi:10.1002/hep.24268
   PubMed Web of Science ®Google Scholar
• Brunt EM, Janney CG, Bisceglie AM, Neuschwander-Tetri BA, and Bacon BR: Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94, 2467–2474, 1999. doi:10.1111/j.1572-0241.1999.01377.x
   PubMed Web of Science ®Google Scholar
• Kanda Y: Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48, 452–458, 2013. doi:10.1038/bmt.2012.244
   PubMed Web of Science ®Google Scholar
• Rm R, and Pm S: Vitamin and trace mineral deficiency and excess. Minerals. Zinc. In: Harrison's Principles of Internal Medicine, Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J (eds.). 19th ed., 2015, pp. 96e-9‒96e-10.
   Google Scholar
• Jang C, Oh SF, Wada S, Rowe GC, Liu L, et al. A branched-chain amino acid metabolite drives vascular fatty acid transport and causes insulin resistance. Nat Med 22, 421–426, 2016. doi:10.1038/nm.4057
   PubMed Web of Science ®Google Scholar
• Goffredo M, Santoro N, Tricò D, Giannini C, D’Adamo E, et al. A branched-chain amino acid-related metabolic signature characterizes obese adolescents with non-alcoholic fatty liver disease. Nutrients 9, 642, 2017. doi:10.3390/nu9070642
   PubMed Web of Science ®Google Scholar
• Newgard CB: Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab 15, 606–614, 2012. doi:10.1016/j.cmet.2012.01.024
   PubMed Web of Science ®Google Scholar
• Fischer JE, Rosen HM, Ebeid AM, James JH, Keane JM, et al. The effect of normalization of plasma amino acids on hepatic encephalopathy in man. Surgery 80, 77–91, 1976.
   PubMed Web of Science ®Google Scholar
• Kawanaka M, Nishino K, Oka T, Urata N, Nakamura J, et al. Tyrosine levels are associated with insulin resistance in patients with nonalcoholic fatty liver disease. Hepat Med 7, 29–35, 2015. doi:10.2147/HMER.S79100
   PubMed Web of Science ®Google Scholar
• Sano A, Kakazu E, Morosawa T, Inoue J, Kogure T, et al. The profiling of plasma free amino acids and the relationship between serum albumin and plasma-branched chain amino acids in chronic liver disease: a single-center retrospective study. J Gastroenterol 53, 978–988, 2018. doi:10.1007/s00535-018-1435-5
   PubMed Web of Science ®Google Scholar
• Prasad AS: Zinc: an overview. Nutrition 11, 93–99, 1995.
   PubMed Web of Science ®Google Scholar
• Truong-Tran AQ, Ho LH, Chai F, and Zalewski PD: Cellular zinc fluxes and the regulation of apoptosis/gene-directed cell death. J Nutr 130, 1459S–1466S, 2000. doi:10.1093/jn/130.5.1459S
   PubMed Web of Science ®Google Scholar
• Prasad AS: Zinc in human health: effect of zinc on immune cells. Mol Med 14, 353–357, 2008. doi:10.2119/2008-00033.Prasad
   PubMed Web of Science ®Google Scholar
• Osredkar J: Copper and zinc, biological role and significance of copper/zinc imbalance. J Clin Toxicol s3, 2011. doi:10.4172/2161-0495.s3-001
   Google Scholar
• Stepien M, Hughes DJ, Hybsier S, Bamia C, Tjonneland A, et al. Circulating copper and zinc levels and risk of hepatobiliary cancers in Europeans. Br J Cancer 116, 688–696, 2017. doi:10.1038/bjc.2017.1
   PubMed Web of Science ®Google Scholar
• Stepien M, Jenab M, Freisling H, Becker NP, Czuban M, et al. Pre-diagnostic copper and zinc biomarkers and colorectal cancer risk in the European prospective investigation into cancer and nutrition cohort. Carcinogenesis 38, 699–707, 2017. doi:10.1093/carcin/bgx051
   PubMed Web of Science ®Google Scholar
• Leone N, Courbon D, Ducimetiere P, and Zureik M: Zinc, copper, and magnesium and risks for all-cause, cancer, and cardiovascular mortality. Epidemiology 17, 308–314, 2006. doi:10.1097/01.ede.0000209454.41466.b7
   PubMed Web of Science ®Google Scholar
• Gumulec J, Masarik M, Adam V, Eckschlager T, Provaznik I, et al. Serum and tissue zinc in epithelial malignancies: a meta-analysis. PLoS One 9, e99790, 2014. doi:10.1371/journal.pone.0099790
   PubMed Web of Science ®Google Scholar
• Poo JL, Rosas-Romero R, Montemayor AC, Isoard F, and Uribe M: Diagnostic value of the copper/zinc ratio in hepatocellular carcinoma: a case control study. J Gastroenterol 38, 45–51, 2003. doi:10.1007/s005350300005
   PubMed Web of Science ®Google Scholar
• Marchesini G, Bugianesi E, Ronchi M, Flamia R, Thomaseth K, et al. Zinc supplementation improves glucose disposal in patients with cirrhosis. Metab Clin Exp 47, 792–798, 1998.
   PubMed Web of Science ®Google Scholar
• Soinio M, Marniemi J, Laakso M, Pyorala K, Lehto S, et al. Serum zinc level and coronary heart disease events in patients with type 2 diabetes. Diabetes Care 30, 523–528, 2007. doi:10.2337/dc06-1682
   PubMed Web of Science ®Google Scholar
• Matsumura H, Nirei K, Nakamura H, Arakawa Y, Higuchi T, et al. Zinc supplementation therapy improves the outcome of patients with chronic hepatitis C. J Clin Biochem Nutr 51, 178–184, 2012. doi:10.3164/jcbn.12-11
   PubMed Web of Science ®Google Scholar
• Hosui A, Kimura E, Abe S, Tanimoto T, Onishi K, et al. Long-term zinc supplementation improves liver function and decreases the risk of developing hepatocellular carcinoma. Nutrients 10, 1955, 2018. doi:10.3390/nu1012
   PubMed Web of Science ®Google Scholar
• Iwata K, Enomoto H, Nishiguchi S, Aizawa N, Sakai Y, et al. Serum zinc value in patients with hepatitis virus-related chronic liver disease: association with the histological degree of liver fibrosis and with the severity of varices in compensated cirrhosis. J Clin Biochem Nutr 55, 147–152, 2014. doi:10.3164/jcbn.14-33
   PubMed Web of Science ®Google Scholar